Zolpidem CR and Hospitalized Patients With Dementia

This study has been completed.
Information provided by (Responsible Party):
Kaloyan Tanev, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
First received: December 18, 2008
Last updated: December 19, 2013
Last verified: December 2013
The purpose of this research study is to compare the effectiveness of Zolpidem CR to that of placebo in improving sleep efficiency in people with dementia admitted to the hospital because of their symptoms. You can participate in this study if you have dementia of the Alzheimer's type or vascular dementia. This study involves placebo; a placebo is a tablet that looks exactly like Zolpidem CR, the study drug, but contains no active study drug. We will use placebos to see if the study results are due to the study drug or due to other reasons. Zolpidem CR is also called Ambien CR and is widely available by prescription. Zolpidem CR is approved by the U.S. Food and Drug Administration (FDA) for the short-term treatment of insomnia (trouble falling or staying asleep).

Condition Intervention
Alzheimer Disease
Dementia, Vascular
Sleep Disorders
Circadian Dysregulation
Drug: Zolpidem CR
Drug: Zolpidem CR placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Sleep efficiency and other actigraphy derived sleep parameters [ Time Frame: 48 hours pre-intervention; week 2-3 post intervention ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Measures of aggression, psychosis, general clinical status, cognitive measures, mood symptoms, length of hospital stay, and percentage of patients who remain on Zolpidem CR at the end of the study. [ Time Frame: 48 hours pre-intervention; week 2-3 post-intervention ] [ Designated as safety issue: Yes ]

Enrollment: 17
Study Start Date: December 2008
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Zolpidem CR
Subjects randomized to Zolpidem CR
Drug: Zolpidem CR
After a 48-hour period of baseline actigraphy and clinical measurements, study subjects will be randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
Other Name: Ambien CR
Placebo Comparator: Placebo
Subjects randomized to Placebo
Drug: Zolpidem CR placebo
After a 48-hour period of baseline actigraphy and clinical measurements, study subjects will be randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.

Detailed Description:
Sleep patterns normally change with age. Sleep/wake cycles appear to be compromised in people suffering from dementia. Most research involving sleep in dementia has involved community dwelling or nursing home residents. Relatively little is known about the sleep patterns of patients with dementia who develop acute behavioral and psychiatric symptoms and necessitate hospitalization. The relationship between sleep disturbances in these patients and behavioral/psychiatric symptoms is also insufficiently studied. The current study will examine these two sets of data (sleep/wake cycles and clinical symptoms) in a population of elderly subjects with Dementia of the Alzheimer's type (DAT) or vascular dementia (VD) during their hospitalization period. We will compare the sleep outcome measures (primarily sleep efficiency) and clinical outcome measures in subjects treated with Zolpidem CR or Placebo. We will utilize a double-blind, randomized, placebo-controlled design to test our hypothesis that targeting sleep disturbances in hospitalized elderly subjects with DAT or VD leads to improvement in sleep and clinical outcomes.

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 60-99 years
  • Clinical diagnosis of Dementia of the Alzheimer's type or Vascular Dementia

Exclusion Criteria:

  1. Subjects who are too agitated to be able to wear the activity monitors;
  2. Subjects who are actively suicidal or homicidal or for whom the clinical treatment team considers participation in the study to be unsuitable;
  3. Subjects with untreated primary sleep disorders
  4. Subjects who receive any hypnotic medications during their participation in the study; Subjects who received hypnotic medications in normal doses prior to Partners Human Subjects Research Application Form Filename: Protocol Summary Version Date: June 1, 2005 5 enrollment may participate in the study if they agree to stop receiving hypnotic medications (see above).
  5. Subjects who are receiving over the counter sleep aids.
  6. Subjects who can not commit to abstaining from alcohol use while in the study.
  7. Subjects with any liver disease.
  8. Subjects with known anaphylactic reaction or angioedema with Zolpidem CR.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00814502

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02144
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Kaloyan S Tanev, MD Massachusetts General Hospital
  More Information

Responsible Party: Kaloyan Tanev, MD, Neuropsychiatrist, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00814502     History of Changes
Other Study ID Numbers: 2008-P-001434/1 
Study First Received: December 18, 2008
Last Updated: December 19, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Alzheimer disease
Dementia, vascular
Circadian dysregulation
Sleep Disorders
Circadian rhythm

Additional relevant MeSH terms:
Alzheimer Disease
Chronobiology Disorders
Dementia, Vascular
Arterial Occlusive Diseases
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Intracranial Arterial Diseases
Intracranial Arteriosclerosis
Mental Disorders
Nervous System Diseases
Neurocognitive Disorders
Neurodegenerative Diseases
Sleep Wake Disorders
Vascular Diseases
Central Nervous System Depressants
GABA Agents
GABA Agonists
GABA-A Receptor Agonists
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2016